Amarin Corp Plc (AMRN)

[Ishouldknowbetter]

Dr Reddy 2nd quarter conf call Q&A on Vascepa: FWIW

Q:So, if you look at Amarin's commentary on their product Vascepa. They've been talking about how the product has been able to retain market shares, because the out-of-pocket expenses for the patient, is actually lower with the brand compared to the generic. Do you see this as a challenge for Dr. Reddy to gain market share in the market?

A:I cannot comment on those. On this stuff, I can tell you that so far we did not see challenge to that much.

Q:And second, on the API supply for our generic Vascepa launch. I just wanted to get a sense on, when do you think we will get to our fair market share for the product? And do -- is API anymore or concern in terms of our ability to ramp up this product, the supplies from partners?

A:At this stage, I don't see concerned with this.

Q:Okay. And when do we think we can get to a fair market share, in your assessment?

A:I don't know what is fair, fair incremental option. I think that the probably in Q2 you should see different results that in the contribution of this product, as we launched the product in the last few days of the quarter and actually Q2, for example, we will be looking for third quarter.

Q:he second question is just on Vascepa. I know you've answered. I'm looking at four-week data that is available now in IQVIA and your market share is under 3% for a drug which say is a second player that's 90% still branded. So why is the market share ramp-up so slower here? And how should it pan out?

A:Normally, when you launch, people are taking the relevant stock and then we are trying to do it. So, our sales is not in accordance to the acute brand.